Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 32

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Anaesthesia+2

Recruiting

Study on the Effectiveness of Spinal Anesthesia vs. Sedation for Turning Breech Babies: Comparing Midazolam and Bupivacaine in Pregnant Women

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Midazolam
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Neurofibromatosis

Recruiting

Imaging Study with 89Zr-Bevacizumab for Predicting Treatment Effects in Patients with NF2-Related Schwannomatosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab Zirconium Zr-89
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Malignant glioma

Recruiting

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Helse Bergen HF

Muscle spasticity

Recruiting

Study of individualized doses of botulinum toxin type A (incobotulinumtoxin) in adults with severe spasticity caused by brain damage

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Dra. Nuria Gutierrez Dubón

Post-traumatic headache

Recruiting

Study on the Safety and Effectiveness of Botulinum Toxin A for Patients with Persistent Post-Traumatic Headache

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Hovedstaden

Intracranial calcification

Recruiting

Study on the Effects of Etidronate on Brain Calcification in Patients with Fahr's Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etidronate Disodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Study Comparing Amitriptyline, Flunarizine, Topiramate, and Propranolol for Preventing Migraines in Primary Care Patients

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Phentermine
  • Sponsor:Institut Universitari D Investigacio En Atencion Primaria Jordi Gol

Duchenne muscular dystrophy

Recruiting

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Medulloblastoma recurrent+1

Recruiting

Study of Axitinib and Etoposide for Children and Young Adults with Refractory or Relapsing Medulloblastoma and Ependymoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Axitinib
  • Sponsor:Centre Hospitalier Regional De Marseille

Myotonic dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings SA

Glioblastoma multiforme+1

Recruiting

Study on the Effects of Dendritic Cell Immunotherapy and Temozolomide in Patients with Glioblastoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Oslo University Hospital HF

Intracranial aneurysm

Recruiting

Study of acetylsalicylic acid to prevent stroke in patients undergoing brain aneurysm coiling procedure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Calgary

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.